Silvan Tuerkcan
Stock Analyst at Citizens
(4.35)
# 384
Out of 5,124 analysts
184
Total ratings
46.67%
Success rate
20.68%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $53.77 | +59.94% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $40.11 | +42.11% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $8.58 | +16.55% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $8.85 | +137.29% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $9.21 | +128.01% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $5.25 | +52.38% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $12.59 | +74.81% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.84 | +226.09% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $16.30 | +108.59% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $33.85 | +32.94% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $43.58 | +14.73% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $5.45 | +175.23% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.53 | +69.97% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.19 | +73.58% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $11.64 | +930.93% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $2.46 | +591.06% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $5.45 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $1.55 | +158.06% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $8.18 | +156.72% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.61 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.80 | +25.00% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $143.42 | +95.23% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.58 | +70.13% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $53.77
Upside: +59.94%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $40.11
Upside: +42.11%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $8.58
Upside: +16.55%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $8.85
Upside: +137.29%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $9.21
Upside: +128.01%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $5.25
Upside: +52.38%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $12.59
Upside: +74.81%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.84
Upside: +226.09%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $16.30
Upside: +108.59%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $33.85
Upside: +32.94%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $43.58
Upside: +14.73%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.45
Upside: +175.23%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.53
Upside: +69.97%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.19
Upside: +73.58%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $11.64
Upside: +930.93%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $2.46
Upside: +591.06%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $5.45
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.55
Upside: +158.06%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $8.18
Upside: +156.72%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.61
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $4.80
Upside: +25.00%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $143.42
Upside: +95.23%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.58
Upside: +70.13%